Alaunos Therapeutics (TCRT) Receivables (2011 - 2025)
Alaunos Therapeutics' (TCRT) quarterly Receivables came in at $3000.0 in Q4 2025, down 40.0% YoY from $5000.0 in Q4 2024, and up 50.0% on a QoQ basis from $2000.0 in Q2 2025.
Alaunos Therapeutics (TCRT) Receivables (2011 - 2025) Analysis & Trends
Alaunos Therapeutics (TCRT) has 15 years of Receivables data on file, last reported at $3000.0 in Q4 2025.
- Quarterly Receivables fell 40.0% year-over-year to $3000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3000.0 (down 40.0% YoY) and the FY2025 annual result came in at $3000.0, down 40.0% from the prior year.
- Receivables grew to $3000.0 in Q4 2025, from $2000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $15.2 million in Q2 2021 to a low of $1000.0 in Q4 2023.
- A 5-year average of $1.9 million and a median of $4000.0 in 2022 frame the typical range for Receivables.
- Annual changes were most pronounced in 2021 — Receivables surged 540.15% — and 2022, when it sank 99.64%.
- Tracing TCRT's Receivables over 5 years: stood at $1.1 million in 2021, then slumped by 99.64% to $4000.0 in 2022, then slumped by 75.0% to $1000.0 in 2023, then soared by 400.0% to $5000.0 in 2024, then sank by 40.0% to $3000.0 in 2025.
- The last three Receivables figures came in at $3000.0 (Q4 2025), $2000.0 (Q2 2025), and $2000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Sep 30, 2022 | 2.91 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 2.61 Mn |
| Jun 30, 2021 | 15.23 Mn |
| Mar 31, 2021 | 5.01 Mn |
| Dec 31, 2020 | 9.37 Mn |
| Sep 30, 2020 | 5.43 Mn |
| Jun 30, 2020 | 4.07 Mn |
| Mar 31, 2020 | 782,000.00 |
| Dec 31, 2019 | 3.33 Mn |
| Sep 30, 2019 | 3.44 Mn |